Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 44 (RPL23AP44) is a processed pseudogene located on human chromosome 5q23.1. It is one of many pseudogenes related to the ribosomal protein L23a (RPL23A), a component of the 60S subunit of the ribosome responsible for protein synthesis. As a pseudogene, RPL23AP44 does not encode a functional protein and currently has no established biological function or known role in disease. There is no evidence that RPL23AP44 serves as a therapeutic target, interacts with drugs, or is used as a biomarker. Key points: RPL23AP44 is a pseudogene (not an active protein-coding gene, but a remnant of functional genes from evolution). It is not a receptor, enzyme, transporter, or typical therapeutic target. There is no documented biological or therapeutic relevance as of current scientific knowledge.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L23a pseudogene 44 (RPL23AP44).